

# Tumor Cell Phenotype Is Sustained by Selective MAPK Oxidation in Mitochondria

Soledad Galli<sup>1</sup>\*, Valeria Gabriela Antico Arciuch<sup>1</sup>\*, Cecilia Poderoso<sup>2</sup>, Daniela Paola Converso<sup>1</sup>, Qiongqiong Zhou<sup>3</sup>, Elisa Bal de Kier Joffé<sup>4</sup>, Enrique Cadenas<sup>3</sup>, Jorge Boczkowski<sup>5</sup>, María Cecilia Carreras<sup>1,6</sup>, Juan José Poderoso<sup>1,7\*</sup>

**1** Laboratory of Oxygen Metabolism, University Hospital, University of Buenos Aires, Buenos Aires, Argentina, **2** Department of Human Biochemistry, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina, **3** Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California, United States of America, **4** Institute of Oncology Ángel H. Roffo, University of Buenos Aires, Buenos Aires, Argentina, **5** Unité INSERM 700, Hôpital Bichat, Paris, France, **6** Department of Clinical Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina, **7** Department of Medicine, University Hospital, University of Buenos Aires, Buenos Aires, Argentina

## Abstract

Mitochondria are major cellular sources of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), the production of which is modulated by oxygen availability and the mitochondrial energy state. An increase of steady-state cell H<sub>2</sub>O<sub>2</sub> concentration is able to control the transition from proliferating to quiescent phenotypes and to signal the end of proliferation; in tumor cells thereby, low H<sub>2</sub>O<sub>2</sub> due to defective mitochondrial metabolism can contribute to sustain proliferation. Mitogen-activated protein kinases (MAPKs) orchestrate signal transduction and recent data indicate that are present in mitochondria and regulated by the redox state. On these bases, we investigated the mechanistic connection of tumor mitochondrial dysfunction, H<sub>2</sub>O<sub>2</sub> yield, and activation of MAPKs in LP07 murine tumor cells with confocal microscopy, *in vivo* imaging and directed mutagenesis. Two redox conditions were examined: low 1 μM H<sub>2</sub>O<sub>2</sub> increased cell proliferation in ERK1/2-dependent manner whereas high 50 μM H<sub>2</sub>O<sub>2</sub> arrested cell cycle by p38 and JNK1/2 activation. Regarding the experimental conditions as a three-compartment model (mitochondria, cytosol, and nuclei), the different responses depended on MAPKs preferential traffic to mitochondria, where a selective activation of either ERK1/2 or p38-JNK1/2 by co-localized upstream kinases (MAPKKs) facilitated their further passage to nuclei. As assessed by mass spectra, MAPKs activation and efficient binding to cognate MAPKKs resulted from oxidation of conserved ERK1/2 or p38-JNK1/2 cysteine domains to sulfinic and sulfonic acids at a definite H<sub>2</sub>O<sub>2</sub> level. Like this, high H<sub>2</sub>O<sub>2</sub> or directed mutation of redox-sensitive ERK2 Cys<sup>214</sup> impeded binding to MEK1/2, caused ERK2 retention in mitochondria and restricted shuttle to nuclei. It is surmised that selective cysteine oxidations adjust the electrostatic forces that participate in a particular MAPK-MAPKK interaction. Considering that tumor mitochondria are dysfunctional, their inability to increase H<sub>2</sub>O<sub>2</sub> yield should disrupt synchronized MAPK oxidations and the regulation of cell cycle leading cells to remain in a proliferating phenotype.

**Citation:** Galli S, Antico Arciuch VG, Poderoso C, Converso DP, Zhou Q, et al. (2008) Tumor Cell Phenotype Is Sustained by Selective MAPK Oxidation in Mitochondria. PLoS ONE 3(6): e2379. doi:10.1371/journal.pone.0002379

**Editor:** Karl-Wilhelm Koch, University of Oldenburg, Germany

**Received:** March 24, 2008; **Accepted:** April 26, 2008; **Published:** June 11, 2008

**Copyright:** © 2008 Galli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by grants from Fundación Pérez Compagn, University of Buenos Aires (Ubacyt M073), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (PIP 5495), Agencia Nacional para la Promoción Científica y Tecnológica (Foncyt, PICT 8468), and NIH (NIA) 5R01AG016718.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: jpoderos@fmed.uba.ar

† These authors contributed equally to this work.

## Introduction

The cell's redox status controls the progression of the cell cycle, including misregulation in cancer [1,2]. Oxidants, such as H<sub>2</sub>O<sub>2</sub>, play an important role in the activation of signaling molecules, which control the complex machinery involved in cell proliferation, differentiation, apoptosis, and senescence. An attractive notion is that the continuous increase in oxidant concentration may trigger disparate cell responses: slight variations in H<sub>2</sub>O<sub>2</sub> concentration (0.7–20 μM H<sub>2</sub>O<sub>2</sub>) help determine normal cell fate, *i.e.*, proliferation [3,4], arrest, senescence or apoptosis [5]. Moreover, an increase in H<sub>2</sub>O<sub>2</sub> steady-state concentration ([H<sub>2</sub>O<sub>2</sub>]<sub>ss</sub>) has been observed *in vivo* in the transition from proliferative hepatoblasts to quiescent and differentiated hepatocytes [6].

Mitochondria are major cellular sources of H<sub>2</sub>O<sub>2</sub>, the production of which is modulated by the mitochondrial energy state and generation of nitric oxide [7]. High mitochondrial H<sub>2</sub>O<sub>2</sub> yield is associated with late rat brain and liver development and signals the end of proliferation [6,8]. From this perspective, development can be understood as a transition from anaerobic metabolism to a five-fold increase in metabolism in mature cells; arrest and differentiation are associated to high mitochondrial activity and membrane potential [9]. Mitochondria are dysfunctional in cancer: the activity of mitochondrial complexes is decreased, the mitochondrial generation of H<sub>2</sub>O<sub>2</sub> is substantially decreased [10], the mitochondrial-K<sup>+</sup> channel axis is suppressed [11], the oxidant-dependent inhibition p38 MAPK is impaired, and p53 suppresses mitochondrion-driven apoptosis [12]. Hence, it may be surmised that tumor cells –like embryonic tissues– live at a very low [H<sub>2</sub>O<sub>2</sub>]<sub>ss</sub> [6,10,13].

Signal transduction is often orchestrated by mitogen-activated protein kinases (MAPKs) [14]. MAPKs are proline-directed serine/threonine kinases [15] that have been classified into at least six subfamilies; from these, ERK1/2, JNK1/2, and p38 are the most extensively studied. ERK1/2 is normally activated by growth signals [16,17]; JNK1/2 and p38 respond to oxidative stress, heat shock, ionizing radiation, and UV light [18,19], and are mainly associated with cell cycle arrest and apoptosis. Of note, oxidative stress may be viewed as a potential carcinogen due to the activation of NF $\kappa$ B or Akt pathways or by causing DNA mutations [20,21]. MAPKs are specifically regulated by a MAPK kinase (MAPKK) [22], *i.e.*, ERK1/2 is activated by MEK1/2, p38 by MKK3, and JNK1/2 by MKK4, among others. MAPKs are sensitive to redox changes: ERK1/2, p38, and JNK1/2 are activated in a variety of cellular systems at different H<sub>2</sub>O<sub>2</sub> concentrations [23,24]. We previously reported that high phosphorylated ERK1/2 content is associated with proliferation and low [H<sub>2</sub>O<sub>2</sub>]<sub>ss</sub> in proliferating embryonic and tumoral tissues, while tumor arrest requires high [H<sub>2</sub>O<sub>2</sub>]<sub>ss</sub> with predominant p38 and JNK1/2 activation [6,10].

To understand the mechanisms of redox modulation by MAPKs, studies have been focused on the oxidative inhibition of phosphatases (MKP) [25] and on the interaction of MAPKKs with antioxidant proteins, such as thioredoxin [26]. However, the direct effects of oxidants on MAPKs and the mechanisms of the transition from proliferation to arrest remain obscure.

Recent data indicate that MAPKs are present in mitochondria, as well as other kinases like PKC and Akt [27,28]. However, the connection among tumor mitochondrial dysfunction, H<sub>2</sub>O<sub>2</sub> yield, and activation of MAPKs still awaits elucidation. In the present work, we provide evidence of MAPKs subcellular redistribution upon activation, including their transit through mitochondria. We demonstrate that the redox state modulates the mitochondrial interaction of MAPKs to MAPKKs by oxidation of conserved cysteine domains of MAPKs to sulfinic and sulfonic acid; this biochemical mechanism determines MAPKs differential activation and traffic to nuclei and ultimately, sustains the phenotype of LP07 tumor cells.

## Results

### H<sub>2</sub>O<sub>2</sub> drives opposite effects on tumor cell cycle progression and signaling

LP07 tumor cells show very low [H<sub>2</sub>O<sub>2</sub>]<sub>ss</sub> (10<sup>-11</sup> M) like embryonic and proliferating tissues [6,10]. In these cells, mitochondria have a low H<sub>2</sub>O<sub>2</sub> production rate but they still respond to oxidative stress as the normal ones do [6,10]. In the present study, we thus examined the redox transition as represented by low (1  $\mu$ M) and high (50  $\mu$ M) H<sub>2</sub>O<sub>2</sub> concentrations. This transition offers the opportunity to test a) the circuit of redox signaling based upon mitochondria and, b) a mechanistic of low H<sub>2</sub>O<sub>2</sub> yield for persistent cell proliferation. We show in Figure 1A that 1  $\mu$ M H<sub>2</sub>O<sub>2</sub> increased LP07 cell proliferation by about 20% ( $p < .05$ ) while 50  $\mu$ M H<sub>2</sub>O<sub>2</sub> oppositely resulted in 40% decrease of cell proliferation ( $p < .05$ ). To evaluate if 50  $\mu$ M H<sub>2</sub>O<sub>2</sub> caused cell cycle arrest or apoptosis, we performed Annexin V staining by flow cytometry. Annexin V-propidium iodide double-negative cells indicated that high H<sub>2</sub>O<sub>2</sub> concentration triggered a transition to a low proliferative state but not to apoptosis, as plotted in Fig. 1B.

The cell cycle modulation by H<sub>2</sub>O<sub>2</sub> described herein was orchestrated by MAPKs. At low H<sub>2</sub>O<sub>2</sub>, redox-induced cell proliferation was almost abolished by ERK1/2 inhibitor U0126. Instead, cell cycle arrest observed with 50  $\mu$ M H<sub>2</sub>O<sub>2</sub> was specifically mediated by activation of p38 and JNK1/2 as shown in Fig. 1C by utilizing SB202129 (p38 inhibitor) or SP600125

(JNK1/2 inhibitor). As inferred by the effect of U0126, the temporal increase of cyclin D1 observed with 1  $\mu$ M H<sub>2</sub>O<sub>2</sub> depended as well on the activation of ERK1/2, while downregulation of cyclin D1 at 50  $\mu$ M of H<sub>2</sub>O<sub>2</sub> was reverted by the p38 and JNK1/2 inhibitors (Fig. 1C and D). It is concluded that cell cycle variations are related to the differential redox activation of extracellular or stress activated MAPK.

### Mitochondria are a meeting point of MAPKs and their upstream activators


Activation of MAPKs in response to a variety of stimuli, including oxidative stress [19,29] has been defined in a two-compartment system: phosphorylation (activation) in cytosol followed by translocation to nuclei [16,30]. Preliminary data on MAPK mitochondrial turnover and its modulation by redox status [24,31] prompted us to examine a three-compartment model for MAPK redistribution upon activation in LP07 cells. To confirm the presence of MAPKs in LP07, cells were labeled with MitoTracker Deep Red and immune stained with anti ERK1/2, p38, and JNK1/2 primary antibodies and secondary antibodies conjugated with Cy3. Images were obtained by confocal microscopy and further analyzed by intensity correlation analysis (ICA) [32] (Fig. 2A); the presence of a diagonal in the 2D fluorescence intensity histogram demonstrated that MAPKs are constitutively expressed in mitochondria. Furthermore, mitochondrial subfractionation showed that MAPKs colocalized with their cognates MEK1/2, MKK3 and MKK4 in the mitochondrial outer membrane and in the intermembrane space (Fig. 2B), as corroborated by the different fraction markers. ERK1/2 molecules were also detected within the organelles by electron microscopy (Fig. 2C).

### Traffic of MAPKs and MAPKKs elicited by redox stimulation involves the mitochondrial compartment

Comparison of the activation kinetics and nuclear accumulation of ERK1/2, JNK1/2, and p38 upon oxidative perturbation yielded a remarkable difference in MAPK responses. After stimulation with 1  $\mu$ M H<sub>2</sub>O<sub>2</sub>, p-ERK1/2 and total ERK1/2 increased in mitochondria, cytosol and nuclei (Fig. 3). An hour after stimulation, p-ERK1/2 returned to the basal level in mitochondria but remained elevated in nuclei. Conversely, 50  $\mu$ M H<sub>2</sub>O<sub>2</sub> entailed a considerable lower rate of ERK1/2 translocation and reduced its activation by ten-fold, and the kinase was retained in mitochondria in detriment of nuclear accumulation (Fig. 3). The sum of the kinetics integrals for each H<sub>2</sub>O<sub>2</sub> treatment remained constant (Fig. 3, circled numbers) which emphasizes the notion of redox interdependence between the mitochondrial and nuclear compartments.

A similar approach to assess the redox regulation of the kinetics JNK1/2 and p38 (Fig. 4) revealed that these were barely affected at low (1  $\mu$ M) H<sub>2</sub>O<sub>2</sub> levels. Instead, upon treatment with 50  $\mu$ M H<sub>2</sub>O<sub>2</sub>, total and phosphorylated JNK1/2 and p38 increased in mitochondria and cytosol and then translocated and accumulated in the nuclei (Fig. 4).

In order to assess the *in vivo* translocation of MAPKs into mitochondria, LP07 cells were transfected with either GFP-hERK2 or GFP-hJNK1, stained them with MitoTracker Deep Red, and continuously followed for MAPK redistribution upon H<sub>2</sub>O<sub>2</sub> stimulation by video confocal microscopy. Low H<sub>2</sub>O<sub>2</sub> caused GFP-hERK2 entrance to mitochondria and subsequent translocation to nuclei (Fig. 5A). A similar behaviour but at high H<sub>2</sub>O<sub>2</sub> stimulation was found for GFP-hJNK1 (Fig. 5B). In the right panel of Figure 5, fluorescence values were plotted every minute during 40 min. In both redox conditions, a previous



**Figure 1. Redox dual modulation of cell fate depends on the activation of ERK1/2 or p38 and JNK1/2.** (A) Cells were counted up to 48 h after stimulation with 1 μM (purple), 50 μM (yellow) or no H<sub>2</sub>O<sub>2</sub> (blue) (mean±s.e.m; n=3, experiment representative of 3, \* *p*<0.05 respect to control values by ANOVA and Scheffe comparison test). (B) Apoptosis was determined by propidium iodide staining (upper panel) and Annexin V (lower panel) by flow cytometry 48 h after H<sub>2</sub>O<sub>2</sub> treatment. (C) [<sup>3</sup>H] thymidine incorporation was measured 48 h after supplementing LP07 cells with 1 μM (purple), 50 μM (yellow) or no H<sub>2</sub>O<sub>2</sub> (blue) (C = control) (mean±s.e.m; n=8, experiment representative of 5, \* *p*<0.05 respect to control values by ANOVA and Scheffe comparison test). When appropriate, cells were preincubated 2 h prior to stimulation with ERK1/2 (U0126), p38 (SB202190) or JNK1/2 (SP600125) inhibitors. (D) Cyclin D1 expression was determined 1 to 3 h after H<sub>2</sub>O<sub>2</sub> treatment (upper panels), and 2 h after stimulation in the presence of MAPK inhibitors as in (C) (medium and lower panels). doi:10.1371/journal.pone.0002379.g001

passage to mitochondria anticipated further traffic to nucleus; however, in the experimental conditions, GFP-hJNK1 turnover resulted faster than that of GFP-hERK2. The patterns described by confocal microscopy were similar to those observed by western blot in Figs. 3 and 4.


The subcellular redistribution of MAPKs and their redox regulation are shown in Fig. S1. 1 μM H<sub>2</sub>O<sub>2</sub> stimulus elicited an initial MEK1/2 outward movement from mitochondria to cytosol (Fig. S1A). As ERK1/2, p-MEK1/2 was retained in mitochondria when stimulated with 50 μM H<sub>2</sub>O<sub>2</sub>. MEK1/2 translocation to nuclei could not be detected in agreement with previous reports [29,33].

The pattern of redistribution and activation of MKK4 (Fig. S1B) and MKK3 (Fig. S1C) following stimulation with high H<sub>2</sub>O<sub>2</sub>

mimicked that of MEK1/2 at 1 μM H<sub>2</sub>O<sub>2</sub>, i.e., the MAPKs moved out from the mitochondria to the cytosol. Fig. S1D is a scheme representative of putative cycle of upstream MAPKs in the studied conditions to carry up MAPKs to nucleus. The degree of MAPK nuclear retention is related to cell cycle progression [16,33]; ERK1/2 retention correlates to cell proliferation, while retention of JNK1/2 and p38 correlates with cell cycle arrest (see Figs. 1 and 2).

#### Oxidation favors differential MAPKs phosphorylation in vitro, but does not change the intrinsic catalytic activity

Direct effects of H<sub>2</sub>O<sub>2</sub> on MAPK catalytic activity were assessed with human recombinant ERK2-GST or immunoprecipitated JNK1/2 and p38 immobilized on agarose. Kinases exposed to



**Figure 2. MAPKs and MAPKs localize in tumor mitochondria.** (A) LP07 cells were stained with MitoTracker Deep Red, fixed and immune stained with anti ERK1/2, JNK1/2 and p38 primary antibodies and secondary antibodies conjugated with Cy3, and analyzed in an Olympus FV1000 confocal microscope. Images directly exported from Olympus Fluoview acquisition program were processed with DIP image software for MATLAB, and a 2D fluorescence intensity histogram was performed. Pixel frequency map displayed on the right. Bar = 10  $\mu$ m. (B) Submitochondrial localization of MAPKs and MAPKs was assessed by western blot. (M: mitochondria; Mpl: mitoplast; OMM: outer mitochondrial membrane; IMS: intermembrane space; IMM: inner mitochondrial membrane; Mx: mitochondrial matrix). Identity of mitochondrial fractions was corroborated with specific antibodies anti complex I 39 kDa subunit, voltage-dependent anion channel (VDAC1), superoxide dismutase II and cytochrome oxidase, subunit VI C. (C) ERK1/2 was detected in LP07 mitochondria by immune labelling and transmission electron microscopy.  
doi:10.1371/journal.pone.0002379.g002


H<sub>2</sub>O<sub>2</sub> were subsequently incubated with substrates or upstream kinases and <sup>32</sup>P- $\gamma$ ATP. Phosphorylation efficiency of ERK2 by MEK1/2 was enhanced at low H<sub>2</sub>O<sub>2</sub> concentrations, whereas decreased at high H<sub>2</sub>O<sub>2</sub> concentration (Fig. 6A). Oppositely, phosphorylation of JNK1/2 and p38 by respective MKK4 and MKK3, was enhanced at high H<sub>2</sub>O<sub>2</sub> level (Fig. 6A). However, H<sub>2</sub>O<sub>2</sub> treatments did not affect the intrinsic catalytic activity of ERK2, JNK1/2, or p38 as proved by absence of effects on the phosphorylation of myelin basic protein (substrate for ERK1/2) or ATF-2 (substrate for p38 and JNK1/2) (Fig. 6A). We therefore surmise that exposure of ERK2, JNK1/2, and p38 to determined H<sub>2</sub>O<sub>2</sub> concentrations increases phosphorylation efficiency by introducing a post-translational modification that would enhance the interaction with their respective MAPKs.

To see whether phosphorylation efficiency varies by redox effects on binding, we treated recombinant MAPKs with 0.1–

10  $\mu$ M H<sub>2</sub>O<sub>2</sub>, and subsequently incubated them with cytosolic or mitochondrial fractions containing the respective MAPKs. Similarly to phosphorylating activities, ERK2-GST binding to MEK1/2 resulted enhanced at low H<sub>2</sub>O<sub>2</sub> level (0.1  $\mu$ M H<sub>2</sub>O<sub>2</sub>) (Fig. 6B) whereas p38-GST and JNK2-GST binding to cognate MAPKs was facilitated at 10  $\mu$ M H<sub>2</sub>O<sub>2</sub> (Fig. 6B). Interestingly, oxidation of ERK2-GST enhanced its dimerization and activation as shown by the interaction with endogenous ERK1/2 and the increase in phosphorylation (Fig. 6B). However, these interactions and ERK2 activation were entirely disrupted at H<sub>2</sub>O<sub>2</sub> concentrations above 1  $\mu$ M.

#### H<sub>2</sub>O<sub>2</sub> modulates ERK-MEK interaction and shuttle to nuclei

To examine whether redox effects on binding *in vivo* resemble the ones observed *in vitro*, LP07 cells were stimulated with 1 and



**Figure 3. Kinetics of ERK1/2 activation and subcellular redistribution upon redox stimuli.** Temporal activation and distribution of ERK1/2 and p-ERK1/2 in the subcellular fractions was followed by western blot. Red and grey circles correspond to 1 and 50  $\mu\text{M}$   $\text{H}_2\text{O}_2$ , respectively; each point integrates densitometries from three separate experiments. Circled numbers represent areas under the curve in arbitrary units per minute calculated with Graph Pad Prism 5 software. A western blot representative of 3 independent experiments is shown. Protein loading was determined with antibodies anti cytochrome oxidase subunit VI C for mitochondria,  $\beta$ -actin for cytosol, and nuclear antigen (PCNA) for nuclei. doi:10.1371/journal.pone.0002379.g003

50  $\mu\text{M}$   $\text{H}_2\text{O}_2$ , p-MEK1/2 and ERK1/2 were precipitated from mitochondria, and cytosol and complex formation was followed by western blot in a pull-down assay. As observed in the *in vitro* assay, *in vivo* p-MEK1/2-ERK1/2 interaction was substantially increased at low  $\text{H}_2\text{O}_2$  and decreased at high  $\text{H}_2\text{O}_2$  concentration (Fig. 7A).

To investigate whether modulation of MEK-ERK interaction in mitochondria affects shuttle to nuclei, cells were transfected with ERK2 and its mutants H230R or Y261N, both with restricted docking to MEK1/2 [33]. At low  $\text{H}_2\text{O}_2$ , transfected ERK2 wild type followed a typical sequence of translocation to mitochondria and nucleus as shown in Figures 2 and 5A. Oppositely, ERK2 mutants with poor binding to MEK1/2 were retained in the organelles in detriment of their translocation to nuclei (Fig. 7B). These findings suggest that the traffic of MAPKs to the nuclei and thus, cell behaviour, depend on  $\text{H}_2\text{O}_2$ -induced changes in their loop of activation, as resulted from redox variations in the domains docking the upstream MAPKs in mitochondria [34,35].

### ERK2, p38, and JNK2 cysteine thiols are specifically oxidized by $\text{H}_2\text{O}_2$

Considering the susceptibility to oxidation of cysteine thiol moieties in proteins, we explored the relevance of these amino acids in the regulation of MAPKs pathways. ERK2-GST immobilized on agarose was exposed to the thiol blocker 4-vinylpyridine (4-VP) and then incubated with a mitochondrial fraction. 4-vinylpyridine treatment resulted in a markedly reduced ERK-MEK interaction (Fig. 8A).

Oxidized cysteines responsible for the differential binding of MAPKs were identified by LC/MS/MS. After treatment with low  $\text{H}_2\text{O}_2$  concentrations (0.1  $\mu\text{M}$ ), the thiol groups of ERK2 Cys<sup>38</sup> and Cys<sup>214</sup> were oxidized to sulfinic ( $-\text{SO}_2\text{H}$ ) and sulfonic acid ( $-\text{SO}_3\text{H}$ ). No oxidation of ERK2 cysteines was detected following treatment with high  $\text{H}_2\text{O}_2$  concentrations (10  $\mu\text{M}$ ) (Table 1).


No JNK2 cysteines were oxidized with 0.1  $\mu\text{M}$   $\text{H}_2\text{O}_2$ , while 1  $\mu\text{M}$   $\text{H}_2\text{O}_2$  oxidized the thiols of Cys<sup>41</sup>, Cys<sup>137</sup>, Cys<sup>177</sup>, and Cys<sup>222</sup> to  $-\text{SO}_2\text{H}$ , and Cys<sup>116</sup> to  $-\text{SO}_3\text{H}$ . It is remarkable that JNK2 Cys<sup>41</sup>, homologous to ERK2 Cys<sup>38</sup>, was sensitive to oxidation while JNK2 Cys<sup>213</sup>, homologous to ERK2 Cys<sup>214</sup>, was not oxidized at any  $\text{H}_2\text{O}_2$  level. In contrast, p38 Cys<sup>162</sup>, homologous to an alternative docking domain of ERK1/2, was oxidized to  $-\text{SO}_3\text{H}$  only after 20  $\mu\text{M}$   $\text{H}_2\text{O}_2$  (Table 1). No methionine, histidine, or tryptophan oxidation, or tyrosine and tryptophan nitrosylation were detected.

### ERK-MEK interaction and ERK shuttle to nuclei depend on mitochondrial oxidation of the redox-sensitive cysteines

In order to assess the role of oxidizable cysteines on ERK activation and redistribution, ERK2 mutants C38A, C214A, and C214E were transfected onto LP07 cells to search for their interaction with MEK1/2.  $\text{H}_2\text{O}_2$  oxidation enhanced wild type ERK2-MEK1/2 interaction (Fig. 8B), as was previously observed in Fig. 6B. However,  $\text{H}_2\text{O}_2$  had no effect on the interaction of MEK1/2 with ERK2 when Cys<sup>214</sup> was substituted by an Ala (C214A) (Fig. 8B). ERK2-MEK1/2 interaction was otherwise enhanced by the replacement of Cys<sup>214</sup> with a Glu (C214E), even in the absence of  $\text{H}_2\text{O}_2$  (Fig. 8B).

Wild type ERK2 translocated to mitochondria and was afterwards retained in nuclei after stimulation with 1  $\mu\text{M}$   $\text{H}_2\text{O}_2$ , as endogenous ERK (Fig. 8C and see Fig. 3). In contrast, ERK2 mutants C38A and C214A were retained in mitochondria in detriment of nuclear entrance (Fig. 8C). p-MEK1/2 was as well retained in mitochondria after transfection with ERK2 mutants C38A and C214A, which indicates that defective oxidation impedes ERK-MEK complex exit from mitochondria (Fig. 8D).

ERK redox-sensitive cysteine domains are well conserved in all MAPKs as well as in other kinases (Table 2). Noteworthy is the fact that both oxidizable Cys<sup>38</sup> in ERK2 and Cys<sup>41</sup> in JNK2 are in



**Figure 4. Kinetics of JNK1/2 and p38 activation and subcellular redistribution upon redox stimuli.** Temporal activation and distribution of JNK1/2 and p38 was followed as in Fig. 3, in analogue experimental conditions.  
doi:10.1371/journal.pone.0002379.g004


the same domain and were oxidized to  $-SO_3H$ , but at different  $H_2O_2$  levels. JNK2 Cys<sup>213</sup> and p38 Cys<sup>48</sup> and Cys<sup>231</sup> all present in these domains, were not oxidized.

## Discussion

In the present study we provide evidence that supports that  $H_2O_2$  drives proliferation and cell cycle arrest by specific MAPKs activation in LP07 cells. Opposite effects elicited by low and high  $H_2O_2$  concentrations have been previously observed in various tumor cell lines [10], as well as in normal tissues [6]; this supports the notion that increases in  $H_2O_2$  concentrations change cell phenotype

by eliciting sequential and opposite responses [3]. This process relies on the alternative activation of either ERK1/2 or JNK1/2 and p38 MAPKs by modulation of the interaction with their cognate MAPKKs. We also confirm the presence of MAPKs and MAPKKs in mitochondria and that these kinases redistribute to the cytosolic and nuclear compartments. The mechanism of MAPK import onto the outer membrane and intermembrane space still awaits elucidation [36]. MAPKs could enter and exit the organelle without previous mitochondrial damage, alike Bcl-2 or Bcl-x<sub>L</sub>, both mitochondrial proteins that translocate to nuclei [37,38].

We show for the first time that modulation of MAPKs interaction with their upstream kinases relies on the oxidation of




**Figure 5. Imaging of MAPKs *in vivo*.** (A) LP07 cells stained with MitoTracker Deep Red and transfected with GFP-hERK2 and stimulated with 1  $\mu$ M  $H_2O_2$ , or (B) transfected with GFP-JNK1 and stimulated with 50  $\mu$ M  $H_2O_2$  were imaged *in vivo*. In (A) and (B) on the right, turnover of MAPKs was monitored with a mask done on the mitochondria with the MitoTracker, or by appearance of GFP green fluorescence in the nucleus. Changes of fluorescence were graphicated when MitoTracker intensity and the respective GFP fluorescence were over 20 in these areas. Images were taken every minute for 40 minutes. Bar = 10  $\mu$ m. doi:10.1371/journal.pone.0002379.g005

cysteines immersed in conserved domains of MAPKs (Table 2). A remarkable finding is that selective kinase activation is based on a differential sensitivity to oxidants, particularly  $H_2O_2$ . Furthermore, efficient ERK2 binding to MEK is achieved by oxidation of two of the five ERK2 cysteine thiols, Cys<sup>38</sup> and Cys<sup>214</sup>, to cysteine sulfinic (-SOH<sub>2</sub>) and sulfonic (-SOH<sub>3</sub>) acid at very low  $H_2O_2$ . Interestingly, ERK2 Cys<sup>38</sup> and Cys<sup>214</sup> are not oxidized at high  $H_2O_2$ . A great variability in the oxidation of cysteine residues at high  $H_2O_2$  concentration was previously found; this fact could be due to the molecular reorganization and competition with water, induced by the oxidant itself. Noteworthy is that JNK2 Cys<sup>41</sup>,


homologous to ERK2 Cys<sup>38</sup>, was sensitive to oxidation while JNK2 Cys<sup>213</sup>, homologous to ERK2 Cys<sup>214</sup>, was not oxidized at any  $H_2O_2$  level. On the other hand, p38 Cys<sup>162</sup>, homologous to an alternative docking domain of rat ERK1/2, was oxidized to -SO<sub>3</sub>H only at high  $H_2O_2$  concentrations (20  $\mu$ M).

ERK2 cysteine oxidation by  $H_2O_2$  proceeds outside its catalytic site, increases binding to MEK1/2 by three to four-fold, modulates activity, and, more importantly, it does not occur at every  $H_2O_2$  concentration, for it can only be achieved at low oxidant level. Cysteine post-translational modifications appear to be critical for the ERK activation pathway and kinase redistribution, and

A




B



**Figure 6. Redox state modulates MAPKs phosphorylation through differential binding to MAPKs *in vitro*.** (A) hERK2-GST, or immunoprecipitated JNK1/2 and p38 were oxidized for 15 min with  $H_2O_2$  and then incubated 30 min with their upstream kinases (MEK1/2, MKK4 or MKK3, respectively), or their substrates, myelin basic protein (MBP) or ATF-2, respectively, in the presence of  $^{32}P$ - $\gamma$ ATP. Total protein content for MAPKs and MAPKs assessed by western blot. Mock experiment (M) was done as control in which the phosphorylating kinases (MAPKK or MAPK, respectively) were omitted. Asterisk denotes  $p < 0.05$  respect to control values by ANOVA and Scheffe comparison test. (B) Human recombinant ERK2-GST, JNK2-GST or p38-GST were immobilized on agarose, oxidized with  $H_2O_2$  and incubated with cytosolic or mitochondrial fractions. Interaction with MAPKs was detected by western blot.

doi:10.1371/journal.pone.0002379.g006






**Figure 7. Redox state adjusts MEK-ERK interaction and regulates traffic from mitochondria to nuclei *in vivo*.** (A) p-MEK1/2 and p-ERK1/2 were immunoprecipitated from mitochondrial or cytosolic extracts of  $H_2O_2$  stimulated cells, run on SDS-PAGE and stained with anti MEK1/2, p-MEK1/2, ERK1/2 and p-ERK1/2 antibodies; bars are mean  $\pm$  s.e.m.;  $n=3$ , western blot representative of 3 independent experiments displayed on the left, and densitometries on the right. Asterisk denotes  $p<0.05$  respect to control values by ANOVA and Scheffe comparison test. (B) Cells were transfected with wild type (WT) ERK2, or ERK2 mutants H230R or Y261N, both with reduced binding capacity to MEK1/2 [33]. After incubation with  $H_2O_2$ , mitochondrial and nuclear fractions were isolated, and ERK2 distribution was detected by western blot using an anti Flag antibody. A western blot representative of 3 independent experiments is shown. Complex IV and PCNA were used as loading control. doi:10.1371/journal.pone.0002379.g007

eventually in cell fate. Mutation of Cys<sup>214</sup> to Ala rendered ERK2 and MEK1/2 accumulation in mitochondria, also observed under high  $H_2O_2$  concentration.

Modulation of enzyme activity by cysteine oxidation to sulfenic acid has been reported: thiol oxidation has been shown to participate in the catalytic mechanism of peroxiredoxins (Prx) isoforms I-VI, which reduce  $H_2O_2$  by forming disulphide [39], sulfenic acid (in Cys<sup>51</sup> in mammals) [40,41]. Prxs are further oxidized to sulfinic acid and inactivated [42], the same that MAPK phosphatase-3 [43] and phosphatase-1B [44]. The cysteine sulfenic acid of Prxs can be reduced to cysteine by ATP-dependent sulfiredoxin [45] or sestrins-Hi95 or sestrin2 [46]. Together, these

facts argue for the reversible oxidation of cysteines as a mechanism of protein activation.

The domains surrounding the cysteines susceptible to oxidation in the former enzymes share an Arg residue (Cys+6 to Cys+11) [47] as well as those in MAPKs. Thiol oxidation requires a low  $pK_a$  for the cysteine group [48]. When located in position Cys+10 or Cys+9, Arg helps decrease  $pK_a$  below 5.8 (normal Cys  $pK_a=8.5$ ), to dissociate Cys-SH to the thiolate (Cys-S<sup>-</sup>) at physiological pH, and to stabilize cysteine sulfenic acid. Because mutation of Cys<sup>214</sup> to glutamic acid enhances ERK-MEK interaction, negative charges must be involved in the interaction and thus, we postulate that cysteine oxidation introduces negative



**Figure 8. ERK interaction with MEK and efficient shuttle to nuclei critically depend on the oxidation of ERK Cys<sup>38</sup> and Cys<sup>214</sup>.** (A) hERK2-GST cysteines were blocked with 4-vinylpyridine (4-VP), and the protein oxidized and subsequently incubated with a mitochondrial fraction as in Fig. 8. (B) Cells were transfected with wild type (WT) ERK2 or ERK2 mutants C38A, C214A, and C214E and stimulated with 1  $\mu$ M H<sub>2</sub>O<sub>2</sub> for 15 min. ERK2 was immunoprecipitated with an anti Flag antibody from isolated mitochondria, and complexes were run on SDS-PAGE and stained with an anti MEK1/2 antibody. (C) Kinetics of differential mitochondrial and nuclear distribution of transfected wild type and ERK2 mutants were followed by western blot after 1  $\mu$ M H<sub>2</sub>O<sub>2</sub> treatment. (D) Kinetics of mitochondrial distribution of p-MEK1/2 when cells were transfected with ERK2 WT, C38A or C214A.

doi:10.1371/journal.pone.0002379.g008

charges with very low  $pK_a$  (<2) that allow the interaction to occur [48]. An attractive idea is that charged cysteines lead MEK or other ligands as they “walk” through arginines to Asp<sup>316</sup> and Asp<sup>319</sup> (Fig. 9A and B), the two essential ERK acidic residues that

integrate the D domain for binding to ligands [32]. p38 Cys<sup>162</sup> negative charges might be attracted to the arginines of upstream ligands, like Arg<sup>104</sup> of MKK3 [49]. With respect to JNK, the probable mechanism of redox binding is controversial, for

**Table 1. Mass spectrometry analysis of ERK2, p38 and JNK2 cysteine modification by H<sub>2</sub>O<sub>2</sub>**

MAPK	H <sub>2</sub> O <sub>2</sub> ( $\mu$ M)	Tryptic peptide	Residue	Charge	MSc	XC	$\Delta$ cn
ERK2	0.1	YTNLSYIGEGAYGMVC(O <sub>3</sub> )SAYDNLNK	Cys <sup>38</sup>	2	34	3.4	0.2
		YTNLSYIGEGAYGMVC(O <sub>2</sub> )SAYDNLNK	Cys <sup>38</sup>	3	NA	5.3	0.13
		SIDIWSVGC(O <sub>2</sub> )ILAEMLSNRPIFP GK	Cys <sup>214</sup>	2	NA	2.9	0.26
p38	20	DLKPSNLAVNEDC(O <sub>3</sub> )ELK	Cys <sup>162</sup>	3	63	3.2	0.27
JNK2	1	YQQLKPIGSGAQGIVC(O <sub>3</sub> )AAFDTVLGINVAVK	Cys <sup>41</sup>	2	98	5.1	0.67
		TLEEFQDVYLVMEMLDANLC(O <sub>3</sub> )QVIHMELDHER	Cys <sup>116</sup>	3	54	NA	NA
		MSYLLYQMLC(O <sub>3</sub> )GIK	Cys <sup>137</sup>	2	31	1.4	0.2
		TAC(O <sub>3</sub> )TNFMMPYVVTR	Cys <sup>177</sup>	2	35	2.8	0.41
		GC(O <sub>3</sub> )VIFQGTDHIDQW NK	Cys <sup>222</sup>	2	37	2.7	0.06

MAPK were oxidized with H<sub>2</sub>O<sub>2</sub>. Tryptic peptide fragment sequence, peptide charge, Mascot Ions Score (MSc), Sequest XC and  $\Delta$ cn value are shown.  $\Delta$ cn stands for the difference in the cross-correlation score between the top two candidate peptides or proteins for a given input data file. NA: not assigned. No oxidation was achieved with ERK2 at 10  $\mu$ M H<sub>2</sub>O<sub>2</sub>, with JNK2 at 0.1  $\mu$ M H<sub>2</sub>O<sub>2</sub> or with p38 at <10  $\mu$ M H<sub>2</sub>O<sub>2</sub>. (O<sub>3</sub>) sulfonic modification, (O<sub>2</sub>) sulfinic modification.

doi:10.1371/journal.pone.0002379.t001

**Table 2.** Redox sensitive cysteine domains.

JNK1	61	IGSGAQGIVCAAYD	JNK1	273	VDIWSVGCIMGEMV
JNK2	32	IGSGAQGIVCAA FD	JNK2	207	VDIWSVGCIMGGLV
ERK2	31	EGAYGMVCAAYD	ERK2	207	IDIWSVGCIMGEMV
ERK1	51	EGAYGMVSAAYD	ERK1	227	VDIWSVGCILAEML
p38	40	GSGAYGSVCAAYD	p38	224	VDIWSVGCIMGEMV
1PME	91	GEGAYGIVCSAYD	1PME	229	IDIWSVGCIMGEMV
MMK1	51	IGHGAIGI VCSAHN	MMK1	185	IDIWSVGCIMGEMV
MPK1	20	GEGAYGIVCSAYD	MPK1	162	DVWSVGCIMGEMV
1TKIA	4	LGREFGIVCAAYD	1TKIA	193	TDIWSVGCIMGEMV
PHKA	3	LGRGVSVVCIH	PHKA	215	DVWSVGCIMGEMV

Alignment of homologue sequences corresponding to regions surrounding Cys<sup>38</sup> and Cys<sup>214</sup> of ERK2 in different kinases. Alignment performed with ExPasy Proteomics Server ([www.ca.expasy.org](http://www.ca.expasy.org)). 1PME (penta mutant ERK2); MMK1 (mitogen-activated protein kinase homologue); MPK1 (mitogen-activated protein kinase); 1TKIA (human titin kinase); PHKA (human phosphorylase kinase subunit alpha).  
doi:10.1371/journal.pone.0002379.t002

oxidation proceeds in several Cys domains. This argues for the possibility that oxidation of multiple cysteines may stabilize the hydrophobic interactions involved in the binding capacity of proteins and also suggests that more than one model of regulation by oxidation could apply for the different biological systems and molecular pathways.

We conclude that proliferation of LP07 cells, and presumably in other cellular systems, depends on sustained oxidation of ERK2 thiols to sulfinic or sulfonic acid achieved at low oxidant yield. If dysfunctional mitochondria are incapable of increasing the oxidative level in cells [10], then they cannot contribute to cell cycle arrest either by oxidation of p38 Cys<sup>162</sup> or by impeding Cys<sup>38</sup> and Cys<sup>214</sup> oxidation in ERK2 and, thus, drive to an uncontrolled cell division and ultimately to cancer.



## Materials and Methods

### Cell line, culture conditions and treatments

LP07 cell line was derived from P07 lung tumor spontaneously arisen in a BALB/c mouse, and extensively characterized [10,50]. Cells were maintained in Dulbecco's modified Eagle's medium nutrient mixture F-12 HAM (D-MEM) with 10% fetal bovine serum (FBS) and 50 µg/ml gentamycin. For treatment, cells were 24 h serum starved and then stimulated with H<sub>2</sub>O<sub>2</sub> and/or the MAPKs inhibitors (2 h prior to H<sub>2</sub>O<sub>2</sub> treatment). When appropriate, cells were seeded onto a 22.1-mm diameter well and transiently transfected with wild-type 3XFlag-CMV7-ERK2 vector, the ERK2 mutants H230R and Y261N (kindly provided by Dr. M. Cobb) or ERK2 mutants C38A, C214A and C214E (Genscript, Piscataway, NJ, USA), with Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions. After transfection, cells were stimulated and harvested, and subcellular fractions were recovered for western blot.

### Isolation of nuclear, mitochondrial and cytosolic fractions

Cells were lysed in MSHE buffer (0.22 M mannitol, 0.07 M sucrose, 0.5 mM EGTA, 2 mM HEPES/KOH, 1 mM phenylmethylsulfonylfluoride (PMSF), 5 µg/ml leupeptin, 5 µg/ml pepstatin, 5 µg/ml aprotinin, 25 mM NaF, and 1 mM sodium orthovanadate, pH 7.4). The homogenate was centrifuged 10 min at 1000 × g (pellet = crude nuclear extract) and 20 min at 10,000 × g

**A****B**

**Figure 9. Scheme of electrostatic guide for ERK-MEK interaction based on cysteine charges.** (A) MKP3-ERK2 interaction based on a crystallographic study (PDB 2GPH). MKP3 peptide is placed on ERK2 docking groove as a product of acidic and hydrophobic interactions with oxidizable cysteines (in red) (modelled with the PyMol program; DeLano Scientific, CA, USA). (B) Scheme based on (A) representing the ligand (yellow ovals) approaching ERK2 (green circles). The ligand "walks" through acidic charges, attracted by Cys<sup>38</sup> and Cys<sup>214</sup>, to finally reach the common docking domain [54].  
doi:10.1371/journal.pone.0002379.g009

(pellet = mitochondria; supernatant = cytosol). Mitochondria were resuspended in MSHE. The crude nuclear extract was washed with buffer A (10 mM Tris, 1.5 mM EDTA, 10% glycerol, 1mM PMSF, 5 µg/ml leupeptin, 5 µg/ml pepstatin, 5 µg/ml aprotinin, 5 mM NaF, and 1 mM sodium orthovanadate, pH 7.4) containing 0.01% NP-40, resuspended in buffer A plus 0.4 M KCl, and incubated 30 min at 4°C. The suspension was centrifuged 30 min at 105000 × g and diluted with buffer A to reduce salt concentration. The purity of the fractions was assessed by western blot with antibodies against complex I or IV (mitochondria), by measuring lactate dehydrogenase activity (cytosol), and by flow cytometry with propidium iodide (nuclei) (data not shown). Protein content was determined by Lowry method.

## Western blot

Proteins separated by SDS-PAGE, were transferred onto PVDF membranes and immunoblotted with antibodies anti total and phosphorylated ERK1/2, p38, JNK1/2, MEK1/2, MKK3, MKK4 (Cell Signaling), cyclin D1 (Santa Cruz), complex I and IV (Molecular Probes) or Flag (Sigma), and then incubated with secondary antibodies conjugated with horseradish peroxidase (GE Health Care). Chemiluminescence was detected with enhanced ECL reagent (GE Health Care).

## Proliferation assays

LP07 cells were seeded onto a 96-well plate ( $8.10^4$  cells/well) and treated as described above for 48 h in the presence of 0.8  $\mu\text{Ci}/\text{well}$  [ $^3\text{H}$ ] thymidine (specific activity, 70 to 90 Ci/mmol; NEN/Dupont, Boston, MA). Then cells were harvested and radioactivity measured in a liquid scintillation counter (Wallac 1414, Turku, Finland). Alternatively, LP07 cells seeded onto a 24-well plate ( $1.10^5$  cells/well) and treated as above, were harvested by trypsinization and counted in a Neubauer chamber in the consecutive days after stimulation.

## Cell growth assay

LP07 were seeded onto a 24-well plate, treated as above, and then harvested and counted in a Neubauer chamber in the consecutive days after stimulation.

## Cell cycle and apoptosis assays

Treated cells were harvested and incubated with (i) 100  $\mu\text{g}/\text{mL}$  propidium iodide in 0.1% sodium citrate, 0.1% Triton X-100 at 4°C overnight in the darkness [51] or (ii) Annexin V-FITC (Immunotech) according to manufacturer's instructions. Cells were run on a FACScalibur flow cytometer (Becton-Dickinson, Mountain View, CA) and analyzed with WinMDI software for windows.

## Fluorescence labeling and confocal microscopy

Cells were grown on cover slides and stained with a specific mitochondrial marker, MitoTracker Deep Red 633 FM (Molecular probes) (100 nM, 45 min at 37°C), fixed in 4% paraformaldehyde, blocked in 1% BSA, 0.3% Triton X-100, PBS, pH 7.4, in a humidified chamber for 1 h, and incubated with primary (anti ERK1/2, JNK1/2 or p38) antibodies and secondary antibodies conjugated with Cy3 for 1h at RT in the same buffer. Cover slides were mounted in Fluorsave mounting media (Calbiochem). For *in vivo* imaging, cells were grown on Lab-Tek Chambered Borosilicate Coverglass System (Nunc), and transfected with GFP-hERK2 or JNK1-GFP, and stained with Mitotracker as described above. Confocal laser scanning microscopy was performed with an Olympus FV1000 using a 63 $\times$ 1.35 NA oil immersion objective. Excitation filters and emission detected with a PDA device were as follows: GFP, 488 nm excitation, 500–560 nm emission; Cy3, 532 nm excitation, 580 $\pm$ 10 nm emission; MitoTracker Deep Red, 633 nm excitation, 650–750 nm emission. Images were acquired with Olympus Fluoview FV10-ASW software and analyzed with DIP image software for MATLAB (TNO, Delft). Images were analyzed by intensity correlation analysis (ICA) [51]; if two structures are part of the same complex or are present at the same place, then their staining intensities should vary in synchrony, whereas if they are on different complexes or structures they will exhibit asynchronous staining. ICA was done with MATLAB software as already developed, studied and reported [52]. Live images were analyzed as follows: a mask was done over the nucleus or over mitochondria when MitoTracker intensity was

over 20, and GFP fluorescence was followed in these areas as well as in the whole cell. Nuclear and mitochondrial GFP fluorescence intensity was corrected for total photobleaching.

## Immune-electron microscopy

Cells were fixed in 4% paraformaldehyde and 0.5% glutaraldehyde in phosphate buffer 0.2 M pH 7.4 for 4 h. After washing in 0.1% glycine the samples were dehydrated in ethanol and embedded in LR White as described [6]. Samples were labeled overnight with anti p-ERK1/2 antibody diluted 1:10, and then washed in 1% BSA and 0.05% Tween in PBS. Then they were incubated with a secondary antibody (1:50) conjugated with 10 nm colloidal gold particles (Sigma anti-rabbit IgG) for 1 h at RT. Grids were washed, fixed in 2% glutaraldehyde for 10 minutes and counterstained in 2% uranyl acetate. Samples were analyzed on a Zeiss EM-C10 transmission electron microscope (50 $\times$  and 100 $\times$  objective) at 80k and photographed with 35 mm Kodak electron film.

## Co-immunoprecipitation assay

MAPKs were immunoprecipitated from cytosolic or mitochondrial fractions (500 and 300  $\mu\text{g}$  of protein, respectively) in lysing buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 0.5% Nonidet P-40, 1 mM MgCl<sub>2</sub>, 1 mM PMSF, 5  $\mu\text{g}/\text{ml}$  leupeptin, 5  $\mu\text{g}/\text{ml}$  pepstatin, 5  $\mu\text{g}/\text{ml}$  aprotinin, 25 mM NaF and 1 mM sodium orthovanadate, pH 7.4). Fractions were rocked for 2 h at 4°C and the immunocomplexes captured with protein A/G-agarose (Santa Cruz) or protein G-agarose (Sigma). Beads were washed in lysing buffer, boiled in loading buffer and run on SDS-PAGE.

## Kinase activity assay

*In vitro* phosphorylation assays were carried out without DTT [53]. GST-hERK2 was utilized and JNK1/2, p38 and the MAPKs were immunoprecipitated in kinase buffer (20 mM HEPES, 2.5 mM MgCl<sub>2</sub>, 10 mM EDTA, 1% NP-40, 0.1% SDS, 40 mM  $\beta$ -glycerophosphate, 2 mM sodium orthovanadate, protease inhibitors, pH 7.5). Myelin basic protein (MBP) and ATF-2 were used as substrates for ERK2 or JNK1/2 and p38, respectively and phosphorylation was assessed by autoradiography. When appropriate, MAPKs were previously oxidized with 0.1–10  $\mu\text{M}$  of H<sub>2</sub>O<sub>2</sub> for 15 min. In mock experiments recombinant MAPKs kinases were absent.

## Pull down assay

Cytosolic or mitochondrial fractions were incubated with human recombinant ERK2-GST, p38-GST or JNK2-GST (Stressgen) oxidized with H<sub>2</sub>O<sub>2</sub> and bound to agarose in lysing buffer for 2 h at 4°C. After incubation, agarose beads were washed in lysing buffer and cracked in loading buffer. Finally, samples were run on SDS-PAGE and detection of MAPKs was assessed. To block the cysteines, proteins were incubated with 4-vinylpyridine (Sigma-Aldrich) for 1 h at RT, and then washed and oxidized. In mock experiments recombinant MAPKs kinases were absent.

## Mass spectrometry

Human ERK2, p38 or JNK2 proteins (Upstate) oxidized with 0.1–20  $\mu\text{M}$  H<sub>2</sub>O<sub>2</sub> were analyzed by mass spectrometry. We used the mutant non-phosphorylatable ERK K52R to avoid autophosphorylation and its putative effect on ERK oxidation. Tryptic digestion was performed with methylated trypsin to reduce autolysis (Promega, Madison, WI). Digestion products were dried

in an APD SpeedVac (ThermoSavant), desalted by ZipTip (Millipore CB18B, Millipore, Billerica, MA) and resuspended in 60% acetic acid for injection by autosampler (Surveyor, ThermoFinnigan). Mass analysis was done in a ThermoFinnigan LCQ Deca XP Plus ion trap mass spectrometer equipped with a nanospray ion source (ThermoFinnigan). Proteins were identified with MS/MS Mascot (Matrix Science) search software using TurboSequest. Mascot and Sequest searches allowed for variable modifications as methionine, histidine or tryptophan oxidation (+16 Da) and cysteine acid reduction (+48 Da), and tyrosine and tryptophan nitrosylation (+45 Da). Sequest search also included variable mono and di-oxidation of cysteine (+16 and +32, respectively).

## Supporting Information

**Figure S1** Redistribution of MAPKs upon redox stimulation. Cellular distribution of (A) MEK1/2 (B) MKK4, and (C) MKK3 was followed as in Fig. 3. In (B) and (C), squares represent nuclei and circles represent mitochondria; red and black symbols indicate 1 and 50  $\mu$ M H<sub>2</sub>O<sub>2</sub>, respectively. (D) On the bases of the experimental findings, a representative scheme proposes a cycle of MPKs to transport cognate kinases from mitochondria to

## References

- Pantano C, Shrivastava P, McElhinney B, Janssen-Heininger Y (2003) Hydrogen peroxide signaling through tumor necrosis factor receptor 1 leads to selective activation of c-Jun-N-terminal kinase. *J Biol Chem* 278: 44091–44096.
- Lou YW, Chen YY, Hsu SF, Chen RK, Lee CL, et al. (2007) Redox regulation of the protein tyrosine phosphatase PTP 1B in cancer cells. *FEBS Lett* 275: 69–88.
- Davies KJA (1999) The broad spectrum of responses to oxidants in proliferating cells: A new paradigm for oxidative stress. *IUBMB Life* 48: 41–47.
- Ramsey MR, Sharpless NE (2006) ROS as a tumour suppressor? *Nat Cell Biol* 8: 1213–1215.
- Antunes F, Cadenas E (2001) Cellular titration of apoptosis with steady state concentrations of H<sub>2</sub>O<sub>2</sub>: submicromolar levels of H<sub>2</sub>O<sub>2</sub> induce apoptosis through Fenton chemistry independent of the cellular thiol state. *Free Rad Biol Med* 30: 1008–1018.
- Carreras MC, Converso DP, Lorenti AS, Barbich M, Levisman DM, et al. (2004) Mitochondrial nitric oxide synthase drives redox signals for proliferation and quiescence in rat liver development. *Hepatology* 40: 157–166.
- Boveris A, Poderoso JJ (2000) Regulation of oxygen metabolism by nitric oxide. In: Louis J. Ignarro, ed. *Nitric Oxide: Biology and Pathobiology*. San Diego, CA: Academic Press. pp 355–368.
- Riobó NA, Melani M, Sanjuán N, Fiszman ML, Gravielle MC, et al. (2002) The modulation of mitochondrial nitric-oxide synthase activity in rat brain development. *J Biol Chem* 277: 42447–42455.
- Heerd BG, Houston MA, Wilson AJ, Augenlicht LH (2003) The intrinsic mitochondrial membrane potential ( $\Delta\psi$ ) is associated with steady-state mitochondrial activity and the extent to which colonic epithelial cells undergo butyrate-mediated growth arrest and apoptosis. *Cancer Res* 63: 6311–6319.
- Galli S, Labato MI, Bal de Kier Joffé E, Carreras MC, Poderoso JJ (2003) Decreased mitochondrial nitric oxide synthase activity and hydrogen peroxide relate persistent tumoral proliferation to embryonic behaviour. *Cancer Res* 63: 6370–6377.
- Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, et al. (2007) A mitochondria-K<sup>+</sup> channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. *Cancer Cell* 11: 37–51.
- Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, et al. (2007) p38 $\alpha$  MAP kinase as a sensor of reactive oxygen species in tumorigenesis. *Cancer Cell* 11: 191–205.
- Chodosh LA (2002) The reciprocal dance between cancer and development. *N Engl J Med* 347: 134–136.
- Pearson G, Robinson F, Beers T, Gibson BE, Xu M, et al. (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. *Endocr Rev* 22: 153–183.
- Cobb MH, Goldsmith EJ (1995) How MAP kinases are regulated. *J Biol Chem* 270: 14843–14846.
- Khokhlatchev AV, Canagarajah B, Wilsbacher J, Robinson M, Atkinson M, et al. (1998) Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. *Cell* 93: 605–615.
- Chen DB, Davis JS (2003) Epidermal growth factor induces c-fos and c-jun mRNA via Raf-1/MEK1/ERK-dependent and -independent pathways in bovine luteal cells. *Mol Cell Endocrinol* 200: 141–154.
- Seo M, Lee YI, Cho CH, Bae CD, Kim IH, et al. (2002) Bi-directional regulation of UV-induced activation of p38 kinase and c-Jun N-terminal kinase by G protein beta gamma-subunits. *J Biol Chem* 277: 24197–24203.
- Carreras MC, Poderoso JJ (2007) Mitochondrial nitric oxide in the signaling of cell integrated responses. *Am. J. Physiol. Cell Physiol* 292: 1569–1580.
- Maeda S, Kamata H, Luo JL, Leffert H, Karin M (2005) IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes cellular hepatocarcinogenesis. *Cell* 121: 977–990.
- Pelicano H, Xu R, Du M, Feng L, Sasaki R, et al. (2006) Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. *J Cell Biol* 175: 913–923.
- Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. *Nature* 410: 37–40.
- Bhat N, Zhang P (1999) Hydrogen peroxide activation of multiple mitogen-activated protein kinases in an oligodendrocyte cell line: role of extracellular signal-regulated kinase in hydrogen peroxide-induced cell death. *J Neurochem* 72: 112–119.
- Alonso M, Melani M, Converso DP, Jaitovich A, Paz C, et al. (2004) Mitochondrial extracellular signal-regulated kinases 1/2 (ERK1/2) are modulated during brain development. *J Neurochem* 89: 248–256.
- Lee YJ, Cho HN, Soh JW, Jhon GJ, Cho CK, et al. (2003) Oxidative stress-induced apoptosis is mediated by ERK1/2 phosphorylation. *Exp Cell Res* 291: 251–266.
- Sumbayev VV, Yasinska IM (2005) Regulation of MAP kinase-dependent apoptotic pathway: implication of reactive oxygen and nitrogen species. *Arch Biochem Biophys* 436: 406–412.
- Poderoso C, Converso DP, Maloberti P, Duarte A, Neuman I, et al. (2008) A mitochondrial kinase complex is essential to mediate an ERK1/2-dependent phosphorylation of a key regulatory protein in steroid biosynthesis. *PLoS ONE* 16: e1443.
- Bijor GN, Jope RS (2003) Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation. *J Neurochem* 87: 1427–1435.
- Boveris A, Cadenas E (1997) Cellular sources and steady-state levels of reactive oxygen species. In: Biadasz Clerch L, Massaro D, eds. *Oxygen and Gene expression and Cellular function*. New York: Marcel Dekker, Inc. pp 1–25.
- Costa M, Marchi M, Cardarelli F, Roy A, Beltram F, et al. (2006) Dynamic regulation of ERK2 nuclear translocation and mobility in living cells. *J Cell Sci* 119: 4952–4963.
- Dougherty CJ, Kubasiak LA, Frazier DP, Li H, Xiong WC, et al. (2004) Mitochondrial signals initiate activation of c-Jun N-terminal kinase (JNK) by hypoxia-reoxygenation. *FASEB J* 18: 1060–1070.
- Li Q, Lau A, Morris TJ, Guo L, Fordyce CB, et al. (2004) Syntaxin 1, G $\alpha_0$ , and N-type calcium channel complex at a presynaptic nerve terminal: Analysis by quantitative immunocolocalization. *J Neurosci* 24: 4070–4081.
- Adachi M, Fukuda M, Nishida E (2000) Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism. *J Cell Biol* 148: 849–856.
- Robinson MJ, Xu BE, Stippes S, Cobb MH (2002) Different domains of the mitogen-activated protein kinases ERK3 and ERK2 direct subcellular localization and upstream specificity in vivo. *J Biol Chem* 277: 5094–5100.

nucleus. Green circles indicate that MAPK are preferentially bound to upstream MAPKs at the different redox states, respectively

Found at: doi:10.1371/journal.pone.0002379.s001 (7.40 MB TIF)

## Acknowledgments

We thank Dr. Philip Stork, University of Oregon Health and Science, Oregon, USA, for ERK-GFP cDNA and Dr. Melanie Cobb, University of Texas Southwestern Medical Center, USA, for 3XFLAG-CMV7-ERK2 and ERK2 mutants H230R and Y261N. We specially thank Prof. Alvaro Estévez from the Burke Medical Research Institute, Cornell University, New York, USA, for the kind gift of pure MAPKs and for helpful comments. We are grateful to Lidia M. López from the LANAIS-ME, Faculty of Medicine, University of Buenos Aires, Argentina for help with electron microscopy and to Dr. Carlos Mendez, Faculty of Medicine, University of Buenos Aires, Argentina, for technical assistance.

## Author Contributions

Conceived and designed the experiments: JP MC SG VA. Performed the experiments: CP DC SG VA QZ. Analyzed the data: EC JP MC VA EB JB. Contributed reagents/materials/analysis tools: CP JB. Wrote the paper: EC JP MC SG VA EB.

35. Zhou T, Sun L, Humphreys J, Goldsmith EJ (2006) Docking interactions induce exposure of activation loop in the MAP kinase ERK2. *Structure* 14: 1011–1019.
36. Soltys BJ, Gupta RS (1999) Mitochondrial-matrix proteins at unexpected locations: are they exported? *Trends Biochem Sci* 24: 174–177.
37. Sánchez-Ceja SG, Reyes-Maldonado E, Vázquez Manríquez ME, López-Luna JJ, Belmont A, et al. (2006) Differential expression of STAT5 and Bcl-x<sub>L</sub>, and high expression of Neu and STAT3 in non-small cell lung carcinoma. *Lung Cancer* 54: 163–168.
38. Hou Y, Gao F, Wang Q, Zhao J, Flagg T, et al. (2007) Bcl-2 impedes DNA mismatch repair by directly regulating the hMSH2-hMSH6 heterodimeric complex. *J Biol Chem* 282: 9279–9287.
39. Veal EA, Findlay VJ, Day AM, Bozonet SM, Evans JM, et al. (2004) A 2-cys peroxiredoxin regulates peroxide-induced oxidation and activation of a stress-activated MAP kinase. *Molecular Cell* 15: 129–139.
40. Yang KS, Kang SW, Woo HA, Hwang SC, Chae HZ, et al. (2002) Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulfinic acid. *J Biol Chem* 277: 38029–38036.
41. Jacob C, Knight I, Winyard PG (2006) Aspects of the biological redox chemistry of cysteine: from simple redox responses to sophisticated signalling pathways. *Biol Chem* 387: 1385–1397.
42. Woo HA, Chae HZ, Hwang SC, Yang KS, Kang SW, et al. (2003) Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation. *Science* 300: 653–656.
43. Seth D, Rudolph J (2006) Redox regulation of MAP kinase phosphatase 3. *Biochemistry* 45: 8476–8487.
44. Van Montfort RL, Congreve M, Tisi D, Carr R, Jhoti H (2003) Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B. *Nature* 423: 773–777.
45. Biteau B, Labarre J, Toledano MB (2003) ATP-dependent reduction of cysteine-sulphinic acid by *S. cerevisiae* sulphiredoxin. *Nature* 425: 980–984.
46. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM (2004) Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. *Science* 304: 596–600.
47. Jeong W, Park SJ, Chang TS, Lee DY, Rhee SG (2006) Molecular mechanism of the reduction of cysteine sulfinic acid of peroxiredoxin to cysteine by mammalian sulfiredoxin. *J Biol Chem* 281: 14400–14407.
48. Kim JR, Yoon HW, Kwon KS, Lee SR, Rhee SG (2000) Identification of proteins containing cysteine residues that are sensitive to oxidation by hydrogen peroxide at neutral pH. *Anal Biochem* 283: 214–221.
49. Heo YS, Kim SK, Seo CI, Kim YK, Sung BJ, et al. (2004) Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. *EMBO J* 23: 2185–2195.
50. Urtreger AJ, Diament MJ, Ranuncolo SM, Vidal MC, Puricelli LI, et al. (2001) New murine cell line derived from spontaneous lung tumor induces paraneoplastic syndromes. *Int J Oncol* 18: 639–647.
51. Nicoletti I, Migliorati G, Oagliacci MC, Grignani F, Riccardi CA (1991) Rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. *J Immunol Meth* 139: 271–279.
52. Kreft M, Milisav I, Potokar M, Zorec R (2004) Automated high throughput colocalization analysis of multichannel confocal images. *Comput Methods Programs Biomed* 74: 63–67.
53. Hochbaum D, Tanos T, Ribeiro-Neto F, Altschuler D, Coso OA (2003) Activation of JNK by Epac is independent of its activity as a Rap guanine nucleotide exchanger. *J Biol Chem* 278: 33738–33746.
54. Tanoue T, Adachi M, Moriguchi T, Nishida E (2000) A conserved docking motif in MAP kinases common to substrates, activators and regulators. *Nat Cell Biol* 2: 110–116.